Haloperidol + Olanzapine
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Schizoaffective Disorder
Conditions
Schizoaffective Disorder, Schizophrenia
Trial Timeline
Mar 1, 1998 → —
NCT ID
NCT00007774About Haloperidol + Olanzapine
Haloperidol + Olanzapine is a approved stage product being developed by Eli Lilly for Schizoaffective Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00007774. Target conditions include Schizoaffective Disorder, Schizophrenia.
What happened to similar drugs?
1 of 4 similar drugs in Schizoaffective Disorder were approved
Approved (1) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00007774 | Approved | Completed |
Competing Products
9 competing products in Schizoaffective Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lurasidone HCl | Sumitomo Pharma | Phase 1 | 29 |
| Placebo + Paliperidone ER + Paliperidone ER | Johnson & Johnson | Phase 3 | 40 |
| Paliperidone ER + Paliperidone ER + Placebo | Johnson & Johnson | Phase 3 | 40 |
| RO6889450 + Placebo + Risperidone | Roche | Phase 2 | 35 |
| RO6889450 + Placebo | Roche | Phase 2 | 27 |
| AMG 581 + Placebo + Midazolam | Amgen | Phase 1 | 29 |
| AMG 581 + Placebo | Amgen | Phase 1 | 29 |
| Aripiprazole + Olanzapine + Risperidone + Quetiapine + Ziprasidone + Aripiprazole + Olanzapine + Risperidone + Quetiapine + Ziprasidone | Pfizer | Phase 3 | 40 |
| Ziprasidone | Pfizer | Approved | 43 |